Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CODEXIS, INC.CDXS · Entity 6428 | Chief Financial Officer | January 01, 2024 | January 03, 2024 |
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Chief Financial Officer | February 20, 2026 | February 20, 2026 |
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Chief Financial Officer | March 14, 2022 | March 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CODEXIS, INC.
Report date January 01, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,791 |
Reported balance
After 2024-01-01 transaction · row 1
1 source rowRow 1 · 2024-01-01 · Grant · Acquired 52,350 · Balance 175,791 F1: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.05 · Expires 2034-01-01 | Direct | 314,125 |
Reported balance
After 2024-01-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-01 · Grant · Acquired 314,125 · Balance 314,125 F2: This option vests and becomes exercisable with respect to 1/3rd of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/36th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates.
F2: This option vests and becomes exercisable with respect to 1/3rd of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/36th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,360 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 55,000 · Balance 72,360 F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 247,500 |
Reported balance
After 2026-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-20 · Grant · Acquired 247,500 · Balance 247,500 F2: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
F2: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Eiger BioPharmaceuticals, Inc.
Report date March 14, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,566 |
Reported balance
After 2022-03-14 transaction · row 1
1 source rowRow 1 · 2022-03-14 · Sale · Disposed 2,266 · Balance 41,566 F1: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 14, 2022 for 5,417 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 14, 2022 for 5,417 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 20, 2026 22:26 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 247,500 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001762893-26-000002 · wk-form4_1771626395.xml · derivative · entry 2 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,500 Underlying: Common Stock · 247,500 shares Expires 2036-02-19 F2 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| February 20, 2026 Filed Feb 20, 2026 22:26 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001762893-26-000002 · wk-form4_1771626395.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,360 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| January 29, 2025 Filed Jan 30, 2025 21:02 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 17,360 | $1.42 | $24,651.20 |
DisclosureSEC source: 0001762893-25-000009 · wk-form4_1738270924.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,360 Read SEC document |
| January 10, 2025 Filed Jan 10, 2025 22:06 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 300,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001762893-25-000006 · wk-form4_1736546757.xml · derivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-01-09 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2026, and the remaining shares subject to the option shall vest monthly thereafter (1/48 of the shares per month for the 36 months following January 2, 2026), subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 02:24 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 314,125 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0000905148-24-000032 · form4.xml · derivative · entry 2 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,125 Underlying: Common Stock · 314,125 shares Expires 2034-01-01 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 1/3rd of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/36th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 02:24 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 52,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000032 · form4.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,791 F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:07 UTC | CODEXIS, INC. CDXS · Entity 6428 | PurchaseCommon Stock | 11,650 | $1.70 | $19,856.26 |
DisclosureSEC source: 0000905148-23-000903 · form4.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,441 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:11 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 372,637 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0001567619-23-002895 · doc1.xml · derivative · entry 2 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,637 Underlying: Common Stock · 372,637 shares Expires 2033-02-10 F2 · derivative.exercise_date: Option was granted pursuant to the Issuer's 2022 Employment Inducement Award Plan and vests and becomes exercisable with respect to 25% of the shares subject thereto on February 10, 2024, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on February 10, 2027, in each case, subject to continued service through the applicable vesting date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:11 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 111,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-002895 · doc1.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,791 F1 · shares: Restricted Stock. The shares vest as to one third of the shares on each yearly anniversary of the date of grant, provided that the Reporting Person provides continuous services to the Issuer as an employee, consultant, director or officer through each such vesting date. Read SEC document |
| March 14, 2022 Filed Mar 14, 2022 21:22 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 2,266 | $5.60 | $12,683.48 |
DisclosureSEC source: 0001567619-22-006948 · doc1.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,566 F1 · shares: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 14, 2022 for 5,417 shares. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 143,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001140361-22-009262 · form4.xml · derivative · entry 2 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Common Stock · 143,000 shares Expires 2032-03-10 F2 · derivative.exercise_date: The option vests in 48 equal monthly installments commencing on the grant date of March 11, 2022, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-009262 · form4.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,832 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest as to 33.3% on each of the first, second and third anniversaries of the grant date of March 11, 2022. F3 · balance_after: Includes shares purchased under the Issuer's Employee Stock Purchase Plans as follows: 434 shares on September 5, 2020, 585 shares on September 3, 2021, and 661 shares on March 5, 2022. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 16:26 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001567619-21-014218 · doc1.xml · derivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-07-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 36 months measured from July 29, 2021 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:32 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 87,000 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001209191-21-031905 · doc4.xml · derivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,000 Underlying: Common Stock · 87,000 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from May 10, 2021 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:38 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 97,500 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0001209191-21-020592 · doc4.xml · derivative · entry 2 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2031-03-11 F3 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from March 12, 2021 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:38 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020592 · doc4.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,152 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest in three equal annual installments measured from March 12, 2021. F2 · balance_after: Includes 274 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on March 5, 2021. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:35 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-20-019001 · doc4.xml · derivative · entry 2 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-03-11 F2 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from March 12, 2020 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 05, 2020 Filed Mar 13, 2020 17:35 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 229 | $7.31 | $1,673.99 |
DisclosureSEC source: 0001209191-20-019001 · doc4.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,628 F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 17:47 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 149 | $9.37 | $1,395.68 |
DisclosureSEC source: 0001209191-19-048805 · doc4.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,399 F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 22, 2019 Filed Apr 22, 2019 21:34 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 1,250 | $11.08 | $13,852.75 |
DisclosureSEC source: 0001209191-19-025564 · doc4.xml · nonDerivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 17:51 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option ( Right to Buy) · Derivative | 90,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-19-002201 · doc4.xml · derivative · entry 1 Ryali Sriram · CIK 0001762893 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The option will vest as to 25% of the option shares on December 17, 2019 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.